Paloma-2 trial
WebFeb 3, 2014 · PALOMA-2 (also known as Study 1008) is a randomized (2:1), multi-center, double blind Phase 3 study that evaluates palbociclib in combination with letrozole versus letrozole plus placebo as first-line treatment for post-menopausal patients with ER+, HER2- advanced breast cancer. WebMar 22, 2024 · In addition, PALOMA-2 reported 22% of the trial population had a DFI < 12 months, compared to 1% in MONALEESA-2 13,15. However, it is important to note that different definitions of DFI and ...
Paloma-2 trial
Did you know?
WebJun 4, 2024 · The PALOMA-2 trial showed that in addition to substantially delaying progressive disease, IBRANCE as first-line treatment, in combination with letrozole, delayed time to chemotherapy (38.1 months vs 29.8 months; HR, 0.73), while maintaining quality of life with no new identified safety issues. WebIn the phase 2, open-label, PALOMA-1 trial, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) versus letrozole alone (hazard ratio, 0.488; 95% CI 0.319‒0.748; P = 0.0004; median PFS, 20.2 vs 10.2 months, respectively) in postmenopausal women with estrogen receptor-positive (ER+)/HER2- ABC.
WebWorked as a certified law clerk conducting preliminary hearings. Conducted 12 preliminary hearings of narcotics sales/possession, assault, … WebThe designs of the MONALEESA-2 and PALOMA-2/PALOMA-1 trials were similar and were, therefore, considered suitable for comparison. Of the MONALEESA-2 ITT …
WebNov 16, 2016 · PALOMA-2 is a randomized (2:1), multicenter, multinational, double-blind Phase 3 study designed to assess the PFS of IBRANCE (125 mg orally once daily for … WebJun 19, 2024 · The clinical patterns of neutropenia and other hematologic toxicities with palbociclib were consistent with observations in PALOMA-1 and PALOMA-3 13, 14, 16 and rarely led to permanent treatment discontinuation in PALOMA-2; although neutropenia occurred at a higher frequency than other AEs, the incidence of febrile neutropenia …
WebNov 16, 2016 · PALOMA-2 is a randomized (2:1), multicenter, multinational, double-blind Phase 3 study designed to assess the PFS of IBRANCE (125 mg orally once daily for three out of four weeks in repeated cycles) in combination with letrozole (2.5 mg once daily continuously) versus letrozole plus placebo as a first-line treatment for postmenopausal …
WebDec 12, 2024 · In the pivotal, double-blind phase III PALOMA-2 study, postmenopausal women with ER-positive/HER2-negative advanced breast cancer were randomized in a 2:1 ratio to frontline treatment with... tproxy tcp and tproxy udpWebJun 10, 2024 · The phase III PALOMA-2 study, conducted by Richard S. Finn, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, and … thermostat downloadWebMay 20, 2016 · In PALOMA-1, an open-label Ph 2 trial, addition of P to L improved median PFS vs L alone (20.2 months [mo] vs 10.2 mo) in pts with first-line ER+/HER2– ABC with … thermostat domusaWebOct 20, 2024 · quently, the randomized, phase 3 trial PALOMA-2 confirmed that palbociclib substantially pro-longed progression-free survival, in combination with letrozole, as first … thermostat douche bloqueWebFinn RS, Martin M, Rugo HS, et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal … thermostat droopPALOMA-2 was designed by an academic steering committee that included representatives from Pfizer, the industry sponsor (see the Supplementary Appendix, available with the full text of this article at NEJM.org). Pfizer supplied the investigators with the treatments used in the study. Data were … See more Hormone-receptorpositive breast cancer represents the largest therapeutic subtype of the disease, accounting for 60 to 65% of all malignant neoplasms of the breast. For more than 50 years, … See more The cyclin-dependent kinases (CDKs) are a large family of serinethreonine kinases that play an important role in regulating cell-cycle progression. The interaction of cyclin D with CDK4 … See more Women with ER-positive, HER2-negative advanced breast cancer were eligible for enrollment if they had not received prior systemic therapy for advanced disease. ER status was … See more In this double-blind, phase 3 study, patients were randomly assigned, in a 2:1 ratio, to receive 125 mg of palbociclib per day, administered … See more thermostat doorbell shareWebAug 29, 2024 · The PALOMA-2 trial was an important clinical trial that randomized patients in the first-line metastatic ER-positive, HER2-negative setting to receive either the standard of care at that time,... tproxy转发